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Anti-melanoma cytolytic T -lymphocyte (CTL) clones 
were derived from peripheral blood lymphocytes of 
HLA-A2 melanoma patient LB265 after stimulation 
with the autologous tun1.or cell line LB265-MEL, 
which showed high expression of melanocyte-lineage 
specific genes. Of 55 CTL clones, 46 recognized 
HLA-A2-restricted antigens. These 46 CTL clones 
were studied for their ability to specifically release 
tumor necrosis factor in the presence of COS cells 
cotransfected with the HLA-A2 gene and the cDNA 
of either tyrosinase, Melan-AlMARTl, Pme117/gpl00, 
gp75/TRPl, or MSH receptor. Six CTL clones recog-
C yto lytic T lymphocytes (CTL) that recognize tumor cell s can often be isolated 6'om m elanoma patients (Boo l1 e( (//, 1994) , Two main procedures have been successfully fo ll owed to determine the nature of the antigens recognized by such 3ntimelanoma CTLs, 
One utili zed a genetic approach based on the transfection of cosmid 
or cDNA librari es and led to the identifi cation of genes MAGE, 
BAGE, GAGE, tyros in ase, and Melan-A /MARTl (Van der Brug-
gen el (//, 1991; Van Pel e( (/ / , 1995), Altemati vely, tandem ma ss 
spectrometry was used to identify HLA-A2-associated non apep-
tides recognized by high-affi ni ty CTLs from m elanoma patients 
(Cox e ( (//, 1994) , 
Besides antigens that correspond to point mutations tJlat give rise 
to wlique tumor-specific antigens, two categories of genes coding 
for antigens recognized on melanomas by CTLs have been so far 
reported, The first category of genes (including MAGE, BAGE, and 
GAGE) is strongly expressed not only in melanomas but also in 
h ead and neck tumors, non-small- cell lung cancers, bladder carci-
noma, and gastric ca rcinoma , By contras t, these genes are silent in 
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nized the Melan-AlMARTl antigen, whereas the re-
maining 40 CTL clones recognized a Pme117/gpl00 
antigen. These 40 anti-Pme117/gpl00 CTL clones 
were all able to lyse T2 cells pulsed with the antigenic 
peptide YLEPGPVT A, as previously reported. The 
T -cell receptor (3 chain hypervariable region was 
sequenced and found to be identical in the 15 CTL 
clones analyzed. Taken together, these d ata show a 
high frequency of Pme117/gpl00-specific T cells in 
autologous antitu~nor CTL clones derived from periph-
eral blood of a melanoma patient. K ey words: IIIelallomal 
CTLli"'IIIll11otl,empy. ] bwest D erllla.tol 107:63-67, 1996 
most normal tissues except testis, w here they might be exclusively 
expressed in germ-line cells that lack expression of MHC mole-
cul es , The antigens encoded by such genes may tJlerefore be tru ly 
tumor-specifi c (for a rev iew, see Van Pel ('( (/ /, 1995) , 
A second category of genes corresponds to proteins th at are 
specific to m elanocyte-lineage cell s, T hese antigens can therefore 
be considered as "differentiation antigens," Tyrosinase, Melan-A I 
MARTI, Pmel17/gpl00, and gp75/TRPl belong to this group, 
Tyrosinase, gp75/TRP1, and Pmel17/gp100 proteins are trans-
m embrane glycoproteins expressed w ithin melanosomes, the mel-
anocyte-specific organell es that are the site of melanin synthesis, 
Tyrosinase is a key enzym e that catalyzes tJle ini tia l steps of melanin 
synthesis (Hearing and Jimenez, 1987), gp 75/TRP1 is the most 
abundant intracellular glycoprotein in m elanocytes and displays 
DHI-2-carboxilic acid oxidase activity in melanogenesis Gimenez-
Cervantes et (//, 1994), Data support the ro le ofPm el17/gplOO in 
melanization as all enzymic or structural component (Kwon et at, 
1991), T he function and localization of th e Melan-A/MART1 
protein is still unknown , 
In our study, we obtained CTL clones from the peripheral blood 
lymphocytes (PBL) of an HLA-2 melanoma patient w hose tumor 
expressed high levels of melanocyte-lineage-specific genes, We 
showed that most of th ese CTL clones recognized two melanocyte-
specific antigens in the context of HLA-A2, namely Melan-AI 
MART1 (6 out of 46 CTL clones) and Pmel17 /gplOO (40 out of 46 
CTL clones), All tJ1e isolated anti-Pmel1 7/gplOO CTL clones 
recognized the same antigenic peptide, the nonam er YLEPGPVTA, 
and the sequences of the T -cel1 receptor (TCR) hypervariable 
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region were fo u nd to b e iden ti ca l for 15 an t i-P m e l1 7/gp100 CTL 
clones. 
MATERIALS AND METH ODS 
Ccll Lincs Tumor cell li ne LB265-MEL was derived from a cervica l 
metastatic lymph node of patient LB265 (HLA-A2 . -A3 , -B7, -B62, -Cw7. 
-Cw9). L13 43-MEL is a melanoma cell line derived from a primary tumor 
(kind gift fi,om Dr. D. Vanneste, Institut Mcdico-C hirurgica l, Tournai, 
Belgium). Melanoma celilincs SK29-MEL and SK23-MEL were" gift fi'om 
Dr L. O ld (Memurial Sloan-Kette ri ng Center, New York). T he melanoma 
ce ll s were cultivated in Iscove's medium supplemented with 10% feta l ca lf 
se rum (GI13CO BR_L. Gaithersburg. M D) . L-arginin e ( 11 6 I11g/ liter), L-
asparagine (36 mg/ liter), and L-glutamine (2 '16 mg/ liter) . COS-7 cells 
(Ameri can Type C ulture Collection CR.L 1651; Rockville, MD) were 
maintained in Du lbecco's modified Eagle's medi um with 10'X, feta l ca lf 
serum. WEHI-164 clone 13 (a gift from Dr. T. Espevik. U ni versity of 
Trondheim, Trondheim. Norway) (Espevik and N issen- Meyer, 1986) and 
T2 ce ll s (Sa lter c ( nl, "\985) were cultured in RPM I- '1640 (GIBCO J31U) 
supp lemented with 10'Yo and 5"1., feta l ca lf serum, respectively. 
Gcncration of CTL Cloncs Auto logous mixed lymphocyte-tumor cul -
tures were essentiall y ca rried o ut as previously described (Herin el nl, 1987). 
13rieAy. lOG FACS-sorted CD8 + T cell s we re stim ulated w ith 105 irradiated 
("100 Gray from a cesium source) LB265-M EL tumor cell s in 2 ml ofl scove's 
medium supplemented with 10% human se rum , L-arginine (116 mg/ li ter), 
L-asparagine (36 mg/ liter). I.-glutamine (216 mg/li ter) , and 2-mercapto-
e thanol (0.05 mM) , 10 U/m l recombinant human in terlcukin-2 (I L-2) 
(donated by Riogen , Geneva, Switzerl 'lIld) and 5 ng/ml of recombina nt 
huma n IL-7 (R&D Systems). Derivation and long te rm cultu re of CTL 
clones were ca rried o ut 'IS previo usly described (Herin cl nl, 1987). 
T u mor N ecr osis Factor (TNF) Assays Melanoma cell lines were tested 
for their ab il ity to stim ulate the production of TNF by CTL clones as 
desctibed previously (Traversari el nl, 1992) . 13rieAy, 3,000 CTLs were 
added to 100 JLI of Iscove med ium supplemented w ith 10% hu man serum 
and 25 U / m l recombinant human I L-2 in microwell s c:l1lta in ing 30,000 
target cell s. Inhi bition of TNF secretion was studied in the presence 3% 
ascitic Auid con ta ining either anti-I-ILA-A2 (B137.2) , anti- H LA- I3 7 (MEl ), 
anti-HLA-13.C (13 1.23.2). or anti- I-ILA class I (W6/32) monoclonal an ti-
bodies. After 24 h , the supernatan t was co llected and its TNF content 
determined by testi ng its cytotoxicity for WEHI-l64 cells (Espevik and 
Nissen-Meyer, 1986) in a MTT colorimetric assay as prev io usly described 
(Traversari el nl. 1992) . 
Transient transfections of COS-7 cell s were pe rfo n11e:! by the DEAE-
dextran-chloroqui ne method (Selden, 1995). 13rieHy, 1.5 X 10" COS-7 cell s 
were cotransfccted with 100 ng of plasmid pcDNA3 (Inv itrogen, San 
Diego, C Al conta ining e ither Pmel17 , gpl00 . gp75/TKP1, or MSH-R 
cDNA. ,'nd 100 ng of plasmid pcDSKa carrying the HLA-A2.1 gene 
(Wolfe l el nl, 1993) . After 24 h , the transfected ce ll s werc tested fo r 
expression of the antigen by their ab il.i ty to ind uce T N F re lease by CTL 
clones. 
Assays for Cytolytic Activity Cytolytic activity was measured as 
desc ribed previously (I-Ic ,-in el nl, 1987). Target cell s were treated for 48 h 
with 50 U / ml of human recombinant in terferon-y (Boehri nger Ingelheim, 
Germany). CTLs and 1000 51 Cr-Iabe led targets were incubated at various 
effecto r-to-target ratios in 96 conica l micro plates in a fi n,,1 vo lume of 200 
JLI. C hrom ium release in the supernatan t was measured afte r 4 h of 
incubation. 
Peptides were synthesized on solid phase using Fmoc IN-(9-
Auorenyl)mcthoxycarbonyl] for tra nsient NH 2-te rminal protectio n, as de-
scribed by Atherton el nl (1981) , and were characterized by mass spcctrom-
etry . The peptides we re > 90% pure as determined by analytica l high-
pressure liquid chromatography. Lyophi l.i zed peptides we re d issolved at 20 
mg/ ml in 10 mM acetic acid and stored at - 80°C. Cell s of the HLA-A2 " 
ccll linc, T2, were 5' C r-labe led for '1 h at 37"C, washed extc11Sively. and 
1000 of the target cel ls were then incubated in 96-well m icropla tes in the 
presencc of various concentrations of peptide for 30 min at 37°C before 
adding CTL clones. After 4 h at 37°C, chronli um re leasc was measured . 
Isolation of cDN As E n c od.ing P m cl17 o r MSH -R Tota l RNA was 
iso lated fi'om LI3265-MEL cell linc using the guanidi ne isothiocyanate-ac id 
phenol method (Davis cl nl, 1986). For polymerase chain reaction (PCK) , 
first strand cDNA was syn thesized from .1 JLg of tota l I<.NA using 
o ligo (dT) ' 5 and Moloney murine leukem ia virus reverse tra nscriptase 
(GIBCO I3R.L). Ampl ification ofPmcl17 and MSH-K genes was perfo rmed 
with specific oligonucleotides: 5'-GGA AGA ACA CAA TGG ATC 
TGG-3' '111d 5'-TCC TGC TTC CTG GAC AGG ACT-3', respective ly, as 
sensc pri mers and 5'-CAC AGC ATC ATA TGA GAG TAC-3' and 
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5' -TCC CTC TGC CCA GCA GCA CAC-3' as antisense primers. T he pi" 
DNA polymerase (Stratagene, La J o lla, CAl was used to avoid PCR - rclated 
erro rs. Twenty-five cycles were perfo rmed as fo llows: 94°C fo r 1 min; 56°C 
for 1 min ; 72°C for 3 min . T hc am pli fi cation products were cloned into 
pcD N A3 plasmid (In vitrogen) . N ucleotide sequences of the two cD NA 
clones were identical to Pmel17 and MSH-R. sequences ava il able fro l11 
databases. Indepcndently, a gp1 00 cDNA. inciden tally corresponding to an 
alternatively sp liced ml<.NA fro m Pmel1 7 gene (Adema el nl, 1994) . was 
obta ined from Dr. G. Adcma (U niversity of Nijrnegcn , T he N ctherl ands). 
T he gp7S/TRP'1 cD N A was kindly prov idcd by D,·. A. H o ughton (Memo-
rial Sloan-Kettering C ancer Centc r, N ew York) and tyrosinase and Melan-
A/MARTl cDNAs werc provided by Dr. V . Dt-ichard (Ludwig Institute, 
13mssels) . 
N or th crn B lo t Analysis Poly(A) + RNA was p repa red using a microfas-
track m RNA cxtraction kit (In vitrogen) . Five micrograms of poly(A) + 
I'lN A, each fi'o m LB265-MEL, SK29-MEL, SK23-MEL, LB43-MEL, and 
NA8-MEL melanoma ceU lincs. was used fo r northern blotting. H ybrid iza-
tion was perfo rmed with a 2039 bp of 32P- Iabclcd probc corresponding to 
nucleotidcs 1-2039 of Pme l1 7 cDN A. A contro l hybridiza tion w ith a 
/3-actin probe was subsequcntly performed on the same membranc. 
T CR V{3 P C R Amplification Single- strand cD NA was prepared fi'om 
poly(A) + l<.NA of anti-Pme l1 7/gpl 00 CTL clones with o ligo (dT) and 
Moloney murinc leukemia virus reverse transcrip tasc (Superscrip t; GIBCO 
I3R.L) . A com bination of TC R. V(3 dcgcnerate primers as S'-primcrs and 
TCR. C/32 primer as 3' - primer were used to ampli fy the TCK va ri ablc 
region as described prev io usly (Broe ren el nl , 1991). T hc PCR cycle p ro fil e 
was as fo llows: 95°C for l min ; 55°C for 2 111in ; 72°C for 3 min. 
Ampli fication was performed over 40 cycles fo llowed by a fina l 15-min 
cxtension period at n oc. PC R. products were cloned in to pBluescrip t-SK 
(Stratagcne) and sequcnced using thc T7 sequencing kit (Pharmacia, 
Uppsa la, Swcdcn) with a C/32-specific primer: 5' -CCTTTTGGGTGTGG-
GAGATC-3' . 
R ES U LTS 
Dcriva tion of Autologous CTL Clones Recognizing Mela-
noma Cell Line LB265-MEL A 7 0-year-old ca u casian wom an , 
p a t ie n t LB265, was examine d i.n 1991 fo r a ri g ht axilla ry m ass t h a t, 
fo ll owing excisio n , p roved to b e a m etastatic ly mph n o d e of a 
m e lan o m a. A few m o nths late r , th e p atien t presen ted cel'v ica l and 
axill a ry m etastatic lymph n o d es, cutan eou s m e tasta tic n o dules, as 
well as ve r teb ra l and lung m ctas tases . In A pr il 1. 993, m e lan o m a cell 
line LB265-MEL was establish e d fi'om a cervical ly mph n o d e 
m etastasis. T his cell tine expressed a hig h level of m elan ocyte-
specific gen es: tyrosinase, M e lan-A/M A R T 1 , Pmel17 /gpl00, 
g p75/TRP1 , and M SH-R bu t n ot M AGE, BAGE, o r GAGE. 
Despite surgery, radioth erap y, and ch e m oth e rapy, p atien t LB 265 
d ie d in N ovembe r 1 993. 
Periph e ral CDS + T cells were purifie d b y sorting PBLs collected 
fro m patie n t LB265 in 1993 and were stimulated ;11 ,,;1,.0 in th e 
p resen ce o fI L-2, lL-7 , and irradi ated LB265-MEL tumo r cell s. T h e 
resp o n der ce ll s were restimulated every week b y addi tio n of 
ir radia ted tumor cells. Afte r 3 week s, we o b ta ine d lymphocytes that 
lysed th e a u to logou s m e lan o m a ce ll s bu t did not lyse the N K -
sen sit ive K 562 cell line. T h e lymphocytes w e re clo n e d by limiting 
d ilu t io n , and 55 stable CTL cl o n es were d e rived fro m thjs mixed 
lymph ocyte-tumo r cul tu res. All clo n es were C D S+ and sh owed 
specific ity fo r th e tumo r cell s, b eca u se th ey lysed LB 265-MEL ceLI s 
but n ot K562 cell s. T h e lytic ac tiv ity of two re presenta tive CTL 
cl o n es (clon es 296/107 and 296/142) is sh own in Fig 1. 
A Pme l17/gpl00 Antigen Is Recognized By HLA-A2.1-
Res tric ted CTL Clones Derived from Autologous PBL s 
T h e 55 CTL cl ones re leased T N F in th e presen ce of LB 265-MEL 
cells. We m easure d th e am o unt of T N F released b y each CTL 
clon e in th e presen ce of antibo dies sp ecifi c e ithe r fo r H LA cl ass I , 
fo r H LA-B an d - C , for H LA-A2, o r for H L A-B7 in o rder to 
establish w hi ch H LA m o lecule w as involved in th e presentatio n of 
th e resp ective an tigen s. In 46 o u t of 55 CTL clon es, T N F p roduc-
tion was signi ficantl y inhibite d b y an ti-HLA class I and an ti-
H LA- A2 m Ab , indicating th a t these 46 CTL cl o n es recognized 
HLA-A2-restricted an tigen s (Fig 2A ). 
To d etermin e wheth e r th ese antigen s w e re en c ode d b y m c lano -
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Figure 1. Anti-Pme117/gpl00 CTL clones 296/107 or 296/142 spe-
cifically lyse autologous melanoma cell line LB265-MEL. LB265-
MEL cells were pretreated with 50 U / ml interferon-y for 48 h prior CO 
incubation with CTL clones 296/107 or 296/142 in a 4-h chromium release 
assay . 
cyte- specifi c genes, we cotransfected COS cell s with the I-ILA-
A2.1 gene and cONAs of either tyros in ase, m elan-A/ MART1 , 
Pmel17 , gp100, gp75 /TRP1 , or MSH -R. Each cD N A was trans-
fected in triplicate COS mi crocuJtures. After 48 h , transfected ceBs 
were tested for their ability to induce T NF release by each of the 46 
CTL clones. Out of 46 CTL clones, 6 produced a large amount of 
T N F in the presence of M elan-A/ MART1-tt'ansfected C OS cells 
(as illustrated in Fig 2B by CTL clone 296/142). T he 40 remaining 
CTL clones recognized COS cells tran sfected by the Pmel1 7 or 
gp100 cDNAs (as illustrated in Fig 2B by CTL clone 296/ 107) , 
which correspond to mRNA isoforms generated by a.lternative 
splicing from a single gene (Adema ct 11 1,1994). 
In order to confi rm that these la tter CTL clones recognized an 
antigen e ncoded by the Pmel17 /gp 100 gene, w e tested their ability 
to re lease TNF sp ecifi cally in the presence of HLA-A2 melanoma 
cell lines that do or do not express this gene as de termin ed by 
northe rn blot ana lysis (Fig 3) . T he two HLA-A2 cell lines LB43-
MEL and SK23-MEL, w hich express gene Pmel17 /gpl00, were 
recognized by these 40 HLA-A2-restricted CTL clones, w hiJe two 
other m elanoma cell lines, SK29-MEL and NA8-MEL, which do 
not express gene Pmel17 1 gpl 00, were not recognized. 
YLEPGPVTA Is the Antigenic Peptide Recognized b y the 
Anti-Pme117/gp100 Autologous CTL Clones Two distinct 
HLA-A2-res tricted antigenic peptides, YLEPGPVT A (amino acids 
280 - 288) (Cox e/ ai, 1994) and LLDGTATLRL (amino acids 
457-466) (Kawakami et 111, 1994), encoded by Pmel17/gplOO gene 
w ere previously and independently ide ntified as the antigen s rec-
ognized by tumor infi ltrating lymphocytes (TILs) derived from two 
m elanoma patients. To determine whethe r these HLA-A2-re-
stricted peptides were recognized by the anti -Pmel1 7/gpl00 CTL 
clones , lysis ofT2 cells, preincubated with 25 nM peptide YLEPG-
PVTA or up to 1 fLM p eptide LLDGTATLRL, was evaluated w ith 
the differe n t CTL clones. The T2 cell line is an HLA-A2 cell line 
with an antigen-processing defect that results in increased capacity 
to present exogen o us p eptide (Cerundolo e/ aI, 1990) . O nly 
nonamer YLEPGPVTA was able to sensitize pulsed T2 cells to lysis 
by the an ti-Pmel17/gp100 CTL clones (as illu strated in Fig 4A for 
CTL clone 296/107). 
T he YLEPGPVTA peptide does no t possess the domin ant HLA-
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Figure 2. Autologous anti-LB265-MEL CTL cloncs recognize mel-
anocyte-spccific antigens presented by HLA-A2 .1. A, stimulation of 
CTL clones 296/107 or 296/142 by the HLA-A2 melanoma ce ll line 
LBZ6S-MEL in the presence of anti-HLA antibodies. Three thousand CTLs 
were co-incubated fo r 24 h with 30,000 LB265-MEL cells seeded in 
microwells and in the presence of IL-2 (25 U/ ml) and the indicated 
monoclonal antibodies (ascitic Auid , di luted 1/30). TNF content of the 
supernatant of th is coculture was measured as dcscribed under Male/ials fl/ld 
Methods. Shown is the mCan and standard deviation calculated £i'om 
triplicate cultures. CTL clones 296/107 and 296/142 are representarive of 
40 and 6 difFerent clones , respectively. B, srimulation ofCTL clone 296/107 
or CTL clones 296/142 by COS-7 cells cotransfected with HLA-A2.1 and 
rnclanocyte-specifi c cDNAs. COS-7 transient transfections were performed 
as described under Materials a/ld M ethods . After 1 day, CTLs WCre added to 
the transfectants, and the TNF content of the supernatant was cstimated 24 
h later. Shown is the mean and standard deviation calculated from trip licate 
COS cransfectiollS. CTL clones 296/107 ,ltld 296/142 are representative of 
40 and 6 di fFerent clones, respective ly. 
A2-anchoring residue in position n ine, even though it is efficiently 
recognized by anti-Pmel17/gp100 CTL clones. Because it has been 
reported that th e m ajori ty of peptides binding to HLA-A2 are 
nonamers carrying valin e, threonine, le ucine, o r isole ucine in the 
n inth position (Falk e/ Il l , 199 1) , we decided to test peptides with 
amino acid substitutions in position r;ine, YLEPGPVTV and 
YLEPGPVTL, fo r th eir abili ty to sensitize pulsed T2 cells to lys is by 
the anti-Pmel17/gplOO CTL clones. T his experiment, reported in 
Fig 4B, clearly demonstrated that T2 cells incubated w itll either the 
originaJ peptide or the substi tute peptides were lysed in the same 
way by CTL clone 296/107. 
Identical TCRf3 Hypervariable Regions Are Expressed by 
the Anti-Pme117/gp100 CTL Clones To determine whether 
a.1l th e anti-Pmel17 /gp100 CTL clones were identical, we 3naJyzed 
the TCR/3 hypervariable region. mRNA extraction and PCR using 
degenerate primers allowed us to amplify the CDR3-like region of 
15 anti-Pmel171 gp1 00 CTL clones including CTL clone 296/107 . 
T llis region, w llich corresponds to the hypervat;able COR3-Li ke 
loops encoded by the VO] junctions, has been postulated to be 
directly involved in antigenic peptide binding (Chotllia e/ aI, 1988; 
C laverie e/ Il l , 1989). T he PCR products were cloned and se-
qu enced . Each of the 15 anti-Pmel17 CTL clones expressed th e 
sa m e TCR/3 chajn (Fig 5). T he sequence of the TCR/3 CDR3-like 
regio n , as defin ed by C hothia c/ II I (1988) , involved the V{33.3 and 
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Figure 3. Activation of CTL clones 296/107 or 296/123 by HLA-A2 
melanoma cell lines correlates with expression of Pmel17/gp100 
mRNA. A. TNF production by CTL clones 296/107 or 296/123 stimulated 
in the presence of five different I-ILA-A2 melanoma cell lin es. Shown is the 
mean of tripljcate cultures that varied from the mean by less than 10%. B. 
northern blot ana lysis of Pmel17 IgplOO in the same melanoma cell lines. 
Each lane contained 5 fLg ofpoly(A + ) ~A. After blotting, the membrane 
was hybridized with a probe containjng the Pmel17/gpl 00 coding sequence 
(nucleotides 1-2039) and washed under stringent conditions. Control 
hybridiza tion was performed on the samc membrane with a /3-actin probe. 
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the J t32 . 7 segments. This experim ent thereby demonstrated that all 
of these CTL clones were derived from the same parental CTL. 
DISCUSSION 
Among human cancers, the immune repertoire to m elanoma has 
been the most widely studied. Analysis of anti-mel anoma immune 
responses provided strong indication that normal differentiation 
antigens on cancer cells are recognized by the h ost. Humoral 
immune responses against these differentiation antigens h ave been 
demonstrated by the presence of IgG autoantibodies against gp75/ 
TRPl antigen (Vijayasaradhi et of, 1990) . MOI"e recently, extensive 
studies of T-cell recognition of human cancers led to the identifi-
cation of several antigens expressed in melanoma, melanocytes, and 
pigmented retinal cells but not in other normal tissues: tyrosinase, 
Melan-A/MART1, Pmel17/gpl00, and gp75/TRPl (reviewed by 
Van Pel et ai, 1995). The role of these antigens as potential targets 
of the immune system was assessed mainly by i,., IJi lro experiments, 
and there is not yet strong evidence that T-cell or antibody 
responses against these antigens lead to immune rejection of cancer 
ill IJiIJo, although some clinical observations made after adoptive 
transfer of TILs suggest a potential role for these antigens as tumor 
rejection antigens (Kawakami el aI, 1994) . 
The peptide YLEPGPVTA, recognized by the PBL-derived CTL 
clones of patient LB265 , was initially identified using biochemical 
techniques and nonautologous T{Ls (Cox el 0/, 1994). Here, by 
investigating the presence of autologous CTL clones directed 
against melanocyte-specific antigens in the pe ripheral blood of the 
HLA-A2 m e lanoma patient LB265, we obtained a large number of 
anti-Pmel17 Igpl 00 CTL clones recognizin g this peptide. Our data 
suggest that a strong T - cell response occurred in the peripheral 
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Figure 4. CTL clone 296/107 recognizes peptide YLEPGPVTA from Pme117/gp100. A, lysis by CTL clone 296/107 ofT2 target cells incubated 
with peptides YLEPGPVTA or LLDGTATLRL from Pme117/gp100. One thousand 51Cr-labeled T2 cells were pulsed with 25 11M peptide YLEPGPVTA 
or 1 fLM peptide LLDGTATLRL and incubated in the presence CTL clones 296/107 at an E/T ratio of 1 0:1. Chromium rel ease waS mcasured after 4 h. T2 
cells alone and LB265-MEL melanoma cclls were also tested as controls. Similar results were obtained with 15 other Pmel17 I gpl OO-speciflc clones. B, 
recognjtion by CTL clones 296/107 ofT2 cells incubated with peptide YLEPGPVTA or two pcp tides substituted in position nine. One thousand 5 1 Cr-Iabeled 
T2 target cells were incubated in 96-well mjcroplates in the presence of va rio liS concentrations of peptide for 30 min at 37°C. Each CTL clone was then added 
at an E/T ratio of 10:1.. Chromium release was measured after 4 h at 37°C. Similar results were obtajncd with three other Pmel17 IgplOO-spccific clones. 
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F i gure 5. TCR/1 junctional nucleotide and amino acid sequences of Ilmel17/gpl00-specific CTL clones recognizing the nonaJuer 
YLEPGPVTA. TCR{3 mRNA was reversed tra n scri b e d and amp li fied u sing TCR V{3 d egenerate prime rs and T C R {32 prime rs . T h e indic ated seq u e n ce 
(GenBank ac cess io n number U 46029), involvin g V {33 .3 and J{32.7 segments, was found in 1 5 Pmel17 /gp I ~O-specifi c CTL clones tested . The sequence of 
the CDR3-1ike regio n as defined by C h othi a Ci al (1988) e n compass residues 95 to 106. 
blood of the melanoma patient and/ or could have been expanded 
il1 I1 itro. T he determination of the actual intensity of the nnti-
Pmel17 /gp100 T -cell response of patient LB265, however, wou ld 
require a more careful analysis of the CTL precursor frequency for 
peptide YLEPGPVT A in the blood of the patient and comparison 
w ith other m elanoma or normal patients. With regard to this, it 
shou ld be stressed that, despite the presence of circulating anti-
melan-A and anti-Pm el17 CTLs, pati ent LB265 did not eventu ally 
reject her tum or. It is not known, however, w hether this failure was 
due to a subsequent loss of these differentiation antigens by tumor 
cells, or to a lack of efi:tcacy of the anti-tumor CTL response ill I1 il1o. 
The seq uence of the TCR{3 CDR3-like region of 15 anti-
Pme117/gpl00 CTL clones was determ in ed and found to involve 
the V{33.3 and J{32.7 gene segments . T his should enable compari-
son w ith the TCR region of others' anti-Pmel17 PBL-derived CTL 
or TILs . T lus observation might contribute to determine the 
potential association of certain TCR V regions with recogn.ition of 
well-defined tumor anti gens, especially melanocyte-lineage anti-
gens, as prev iously suggested (Sensi et nl, 1995). Such data may be 
useful in antimelanoma immunotherapy, as it could lead to several 
c linical applications such as adoptive transfe r in melanoma patients 
of CD8 + T cells se lected on the basis of speci.fic TCR V gene 
expression , o r analys is of ill I1 il1o evolu tion of the specific T -cell 
response directed against well-defined tumor antigens . 
In conclusion , our results demonstrate the existence of CTL 
clones recognizing the same Pmel1 7 /gpl 00 peptide YLEPGPVTA 
in the peripheral blood of 3n HLA-A2.1 melanoma patient w hose 
tumor expressed high levels of m elanocyte-specific genes. T he 
potentia l uti ljty of this antigen is emphasi zed by objective regres-
sions of melanoma metastases after adoptive transfer of T ILs 
populations, whi ch were shown retrospectively to include anti-
Pmel1 7 /gpl 00 CTLs (Kawaka mi el nl, 1994) . Moreover, associa-
tion of vitiligo with prolonged survival and spontaneous regression 
of m elanoma, although not observed in patient LB265, supports the 
role of the differentiation antigens as potentia lly effective targets for 
immune responses leading to tumor rej ection ill 11 ;110 (Bystryn el ai , 
1987). 
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